• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.17%

    Immunomedics Inc. (IMMU)

    -NasdaqGM
    4.41 Up 0.13(3.04%) Dec 24, 1:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Immunomedics Inc.
    300 The American Road
    Morris Plains, NJ 07950
    United States - Map
    Phone: 973-605-8200
    Fax: 973-605-8282
    Website: http://www.immunomedics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:120

    Business Summary 

    Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Immunomedics Inc.

    Corporate Governance 
    Immunomedics Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 3. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 1; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. David M. Goldenberg , 76
    Founder, Chairman, Chief Medical Officer, Chief Scientific Officer and Director of IBC Pharmaceuticals Inc
    1.02M0.00
    Ms. Cynthia L. Sullivan , 59
    Chief Exec. Officer, Pres, Director and Pres of Ibc Pharmaceuticals Inc
    857.00K0.00
    Mr. Peter P. Pfreundschuh , 45
    Chief Financial Officer and VP of Fin.
    312.00K0.00
    Mr. Gerard G. Gorman , 63
    Consultant
    289.00K0.00
    Ms. Phyllis Parker ,
    Director of Admin. and Sec.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders